| Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method. | |
| | |
MedLine Citation:
|
PMID: 22300415 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Purpose: Pranlukast, one of the potential therapeutic tools in the treatment of asthma, has limited clinical applications due to its poor water solubility. The study is aimed to provide a platform for better utilizing pranlukast with enhancement of the dissolution rate and, thus, the oral bioavailability of pranluka'st by preparing nanosuspensions through high-pressure homogenization method. Method: Poloxamer407 and PEG200 were chosen as stabilizer and surfactant. The formulation was investigated systematically with the dissolution tests as predominant method. Nanosuspensions were prepared by programmed high-pressure homogenization method. The product was characterized by particle size analysis, TEM and XRD are evaluated by in vitro dissolution tests and in vivo absorption examination. In addition, nanosuspensions with only pranlukast were prepared and compared with formulated nanosuspensions. Results: The optimal values of formulation were 0.5% (w/v) pranlukast with 0.375% (w/v) Poloxamer407, 0.375% (w/v) PEG200 and the screened programming homogenizing procedure parameters were 680 bar for the first 15 circles, 1048 bar for the next 9 circles and 1500 bar for the last 9 circles. Nanosuspensions of 318.2 ± 7.3 nm, -29.3 ± 0.8 mV were obtained. The XRD analysis indicated no change of crystalline occurred in the process of homogenization. The in vitro dissolution behavior of nanosuspensions exhibited complete release in 30 min with a remarkable fast dissolution rate. The in vivo bioavailability of formulated pranlukast nanosuspensions demonstrated its enhancement of fast onset of therapeutic drug effects with 4.38-fold improved compared to that of raw crystals. Conclusion: The study provides a feasible, practical thinking of industry development in the clinical use of pranlukast. |
| | |
Authors:
|
Lan Wang; Yanli Hao; Nan Liu; Mingshu Ma; Zhe Yin; Xiaoning Zhang |
Related Documents
:
|
22278625 - Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcificatio... 22569895 - Stability and bioavailability of vitamin d nanoencapsulated in casein micelles. 1381765 - Further observations to confirm the arrhythmia mechanism-specific effects of flunarizine. 8135425 - Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity. 2986025 - Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone, and pr... 3731535 - Effect of regular alcohol use on blood pressure control in treated hypertensive subject... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-3 |
Journal Detail:
|
Title: Drug development and industrial pharmacy Volume: - ISSN: 1520-5762 ISO Abbreviation: - Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-3 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7802620 Medline TA: Drug Dev Ind Pharm Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Laboratory of Pharmaceutics, School of Medicine, Tsinghua University , Beijing , China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: PLGA-Laponite-F68 Nanocomposite Vesicles through Single-Step Double Emulsion Method for the Controll...
Next Document: The effectiveness of a standardised preoperative preparation in reducing child and parent anxiety: a...